AVNS vs. PRCT, NARI, IRTC, CNMD, NVCR, ESTA, AORT, SILK, EYE, and PLSE
Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include PROCEPT BioRobotics (PRCT), Inari Medical (NARI), iRhythm Technologies (IRTC), CONMED (CNMD), NovoCure (NVCR), Establishment Labs (ESTA), Artivion (AORT), Silk Road Medical (SILK), National Vision (EYE), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry.
Avanos Medical (NYSE:AVNS) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
PROCEPT BioRobotics has a consensus price target of $62.60, suggesting a potential upside of 0.05%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Avanos Medical.
In the previous week, Avanos Medical and Avanos Medical both had 5 articles in the media. PROCEPT BioRobotics' average media sentiment score of 0.74 beat Avanos Medical's score of 0.71 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.
Avanos Medical has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
Avanos Medical has a net margin of -9.15% compared to PROCEPT BioRobotics' net margin of -66.12%. Avanos Medical's return on equity of 4.10% beat PROCEPT BioRobotics' return on equity.
Avanos Medical has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Avanos Medical received 54 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 63.04% of users gave PROCEPT BioRobotics an outperform vote while only 54.97% of users gave Avanos Medical an outperform vote.
95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.9% of Avanos Medical shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Avanos Medical beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.
Get Avanos Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avanos Medical Competitors List
Related Companies and Tools
